艾尔建(英語:Allergan plc),或译愛力根,是一家爱尔兰制药公司,AbbVie的子公司。[2][1]

艾尔建
Allergan plc
公司類型子公司
ISINIE00BY9D5467
成立2013年5月16日,​11年前​(2013-05-16
總部 爱尔兰都柏林
營業據點數40家生产工厂,27家全球研发中心和全球销售营销部门
業務範圍100个国家
产业制药工程
營業額 157.87亿美元 (2018年)
净利润 51.42亿美元 (2018年)
資產 1017.87亿美元 (2018年)
資產淨值 651.31亿美元 (2018年)
所有權者艾伯维 编辑维基数据
員工人數17,800 (2018)
网站www.allergan.com
備註[1]

历史

1950年创建于美国欧文,1970年在纽约证券交易所挂牌上市,2009年进入中国市场,2015年被爱尔兰制药公司阿特维斯以700亿美元收购,并且将总部迁往都柏林以避税。[3][4]合并后的公司依然使用原名。

2015年11月23日,輝瑞宣布斥資1,600億美元打算收购艾尔建。但在2016年4月6日,因奥巴马政府禁止税负倒置,輝瑞取消收購計劃[5],辉瑞赔偿艾尔建中止协议补偿金1.5亿美元[6][7]

2019年6月,美国制药公司AbbVie宣布已达成协议,以630亿美元收购艾尔建。

 
艾尔建美国总部
 
艾尔建爱尔兰总部

参考来源

  1. ^ 1.0 1.1 Allergan plc 2018 Form 10-K Annual Report. U.S. Securities and Exchange Commission. [2019-09-30]. (原始内容存档于2019-09-30). 
  2. ^ Jonathan D. Rockoff; Nina Trentmann. New Tax Law Haunts Inversion Deals. The Wall Street Journal. 11 February 2018. Similarly, Allergan, a drugmaker that moved its headquarters to Ireland after a 2013 acquisition but gets about 80% of revenue in the U.S., expects the loss of deductions on intercompany loans will largely be balanced out by lower taxes on its U.S. sales. 
  3. ^ From Actavis to Allergan: One pharma company's wild dealmaking journey. Forbes Magazine. 30 July 2015 [2019-09-30]. (原始内容存档于2020-09-27). For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud. 
  4. ^ Liz Hoffman. The Tax Inversion Wave Keeps Rolling. Wall Street Journal. 7 July 2015 [2019-09-30]. (原始内容存档于2019-04-17). Horizon and other inverted companies are using their new, lower tax rates to turbocharge corporate takeovers. Applying those rates, often in the midteens, to profits of companies in the U.S., with a federal corporate rate of 35%, can yield extra savings on top of those traditionally wrung from mergers. Moreover, unlike the U.S., Ireland and most other countries, only tax profits earned in-country, giving companies the freedom and incentive to shift income to still-lower-tax jurisdictions. 
  5. ^ Pfizer seals $160bn Allergan deal to create drugs giant. BBC News. November 23, 2015 [2022-02-18]. (原始内容存档于2020-11-27). 
  6. ^ Rockoff, Jonathan. Pfizer Walks Away From Allergan Deal. The Wall Street Journal. April 6, 2016 [2022-02-18]. (原始内容 存档于2022-02-18). 
  7. ^ Hoffman, Richard Rubin and Liz. New Rules on Tax Inversions Threaten Pfizer-Allergan Deal. Wall Street Journal. 2016-04-05 [2020-04-08]. ISSN 0099-9660. (原始内容存档于2022-02-18) (美国英语). 

外部链接